Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90)

Heart

Volumn 97, Issue 7, 2011, Pages 585-586

  Stewart, Kirsty ^a   Walters, Matthew ^b   Dawson, Jesse ^b  

^a NHS EDUCATION FOR SCOTLAND   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; GENERIC DRUG; PLACEBO;

BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SHORT SURVEY; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ASPIRIN; CONSTRICTION, PATHOLOGIC; DELAYED-ACTION PREPARATIONS; DIPYRIDAMOLE; DRUGS, GENERIC; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; TICLOPIDINE; VASCULAR DISEASES;

EID: 79952515935     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.219717     Document Type: Short Survey

References (13)

1. National Institute for Health and Clinical Excellence. Clopidogrel and modifiedrelease dipyridamole for the prevention of occlusive vascular events (review of technology appraisal guidance 90). London: National Institute for Health and Clinical Excellence, 2010.
2. National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (technology appraisal guidance 90). London: National Institute for Health and Clinical Excellence, 2005.
3. Anon. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE steering committee. Lancet 1996;348:1329-39.
4. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13. (Pubitemid 26402780)
5. Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162-8. (Pubitemid 40054197)
6. Anon. European stroke prevention study. ESPS group. Stroke 1990;21:1122-30.
7. Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-73.
8. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
9. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007;370:1432-42. (Pubitemid 47576154)
10. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
11. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
12. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-40. (Pubitemid 40632440)
13. The Active Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.